Surmodics Inc (SRDX)

$29.12 -0.78 (-2.61%)
Market Cap 416.36M
Revenue (ttm) 126.08M
Net Income (ttm) -11.54M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -9.15%
Debt to Equity Ratio 0.27
Volume 92,800
Avg Vol 250,788
Day's Range N/A - N/A
Shares Out 14.30M
Stochastic %K 4%
Beta 1.31
Analysts Hold
Price Target $43.00

Company Profile

Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deploy...

Industry: Medical Devices
Sector: Healthcare
Phone: 952 500 7000
Fax: 952 500 7001
Address:
9924 West 74th Street, Eden Prairie, United States
highnihilism
highnihilism Oct. 1 at 11:46 AM
$QCML Graniteshares 2X Long $QCOM Daily ETF Trades: 3 | Total $: 1.3 K | 0.48 × 90-Day Avg $: 2.6 K | Call $: 560 | Put $: 700 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $JQUA JPMorgan US Quality Factor ETF Trades: 6 | Total $: 9.4 K | 3.76 × 90-Day Avg $: 2.5 K | Call $: 560 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $SRDX Surmodics Trades: 6 | Total $: 761 | 0.01 × 90-Day Avg $: 66.1 K | Call $: 556 | Put $: 205 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $CQP Cheniere Energy Partners Trades: 11 | Total $: 9.5 K | 0.65 × 90-Day Avg $: 14.6 K | Call $: 555 | Put $: 8.9 K | Single-Leg: 100% | Multi-Leg: 0% | Contingent: –
0 · Reply
highnihilism
highnihilism Sep. 17 at 10:13 AM
IWM: Russell 2000 → $SRDX Surmodics $SVV Savers Value Village $THFF First Financial $PCYO Pure Cycle $SCVL Shoe Carnival
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 4 at 12:44 PM
$SRDX Great piece that accurately captures SRDX's current position. So if you want to refresh your understanding of SRDX or learn about SRDX for the first time, this is essential reading. https://beyondspx.com/quote/SRDX/surmodics-innovation-s-crucible-amidst-merger-uncertainty-nasdaq-srdx#analysis
0 · Reply
theoptionsplug
theoptionsplug Aug. 21 at 5:00 AM
Things to Watch Thursday (PART 2/2) 👁️ 🗣️7:30AM - Atlanta Fed President Raphael Bostic speaks 💼8:30AM - Initial jobless claims are released 📊9:45AM - Global flash PMIs for August arrive, with focus on U.S. tariffs after July’s manufacturing PMI slipped below 50. 🏘️10AM - Existing home sales data for July is released 👟 M&A Vote – Foot Locker $FL holds a shareholder meeting on its proposed merger with Dick’s Sporting Goods $DKS ⚖️ FTC Trial – Proceedings begin in the FTC’s attempt to block GTCR’s acquisition of Surmodics $SRDX
0 · Reply
ZacksResearch
ZacksResearch Aug. 12 at 6:34 PM
$SRDX surprises with a Q3 earnings beat, but challenges linger! 📊 SRDX delivered a surprise adjusted EPS of 6 cents, defying the Zacks Consensus Estimate of a 21-cent loss. However, fiscal Q3 revenues dipped 2.6% year over year, with declining Medical Device sales and a shrinking gross margin raising concerns. 📉 Complete risk/reward breakdown here 👉 https://www.zacks.com/stock/news/2703118/srdx-stock-up-following-q3-earnings-beat-gross-margin-contracts?cid=sm-stocktwits-2-2703118-body-7524&ADID=SYND_STOCKTWITS_TWEET_2_2703118_BODY_7524
0 · Reply
ZacksResearch
ZacksResearch Aug. 12 at 5:34 PM
$SRDX pops on Q3 beat 🔼 Earnings topped expectations with a narrower loss and revenue above estimates, even as SurVeil DCB sales slipped and gross margin contracted. Full earnings recap here 👉 https://www.zacks.com/stock/news/2703118/srdx-stock-up-following-q3-earnings-beat-gross-margin-contracts?cid=sm-stocktwits-2-2703118-teaser-7523&ADID=SYND_STOCKTWITS_TWEET_2_2703118_TEASER_7523
0 · Reply
traderhr
traderhr Aug. 12 at 9:47 AM
The stock chart for Surmodics shows a recent consolidation phase, with price movement stabilizing around the 38.00 level after a notable surge. The upper Bollinger Band indicates potential resistance at $SRDX #tradeideas $SPX $DJIA
0 · Reply
JarvisFlow
JarvisFlow Aug. 11 at 12:00 PM
Barrington Research has adjusted their stance on Surmodics ( $SRDX ), setting the rating to Market Perform.
0 · Reply
capribagholder
capribagholder Jun. 7 at 1:39 PM
$SRDX am i only one here hoping for 43 dollars 💸
0 · Reply
Estimize
Estimize Jun. 3 at 11:00 AM
Wall St is expecting -0.19 EPS for $SRDX Q3 [Reporting 07/30 BMO] http://www.estimize.com/intro/srdx?chart=historical&metric_name=eps&utm_c
0 · Reply
Latest News on SRDX
Surmodics Reports Third Quarter of Fiscal Year 2025 Financial Results; Updates Fiscal Year 2025 Financial Guidance

Aug 8, 2025, 7:00 AM EDT - 2 months ago

Surmodics Reports Third Quarter of Fiscal Year 2025 Financial Results; Updates Fiscal Year 2025 Financial Guidance

Surmodics to Report Third Quarter of Fiscal 2025 Financial Results on August 8

Aug 6, 2025, 4:05 PM EDT - 2 months ago

Surmodics to Report Third Quarter of Fiscal 2025 Financial Results on August 8

Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance

Apr 30, 2025, 7:00 AM EDT - 5 months ago

Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance

Surmodics to Report Second Quarter of Fiscal 2025 Financial Results on April 30

Apr 28, 2025, 6:00 PM EDT - 5 months ago

Surmodics to Report Second Quarter of Fiscal 2025 Financial Results on April 30

Surmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil™ Drug-Coated Balloon

Apr 22, 2025, 7:00 AM EDT - 5 months ago

Surmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil™ Drug-Coated Balloon

Surmodics Announces Commercial Release of Pounce™ XL Thrombectomy System, Enabling Rapid Non-Surgical Clot Removal in Iliac and Femoral Arteries

Apr 3, 2025, 7:00 AM EDT - 6 months ago

Surmodics Announces Commercial Release of Pounce™ XL Thrombectomy System, Enabling Rapid Non-Surgical Clot Removal in Iliac and Femoral Arteries

Surmodics Issues Statement on U.S. Federal Trade Commission Challenge to Proposed Acquisition of Surmodics by Funds Affiliated with GTCR

Mar 6, 2025, 9:00 PM EST - 7 months ago

Surmodics Issues Statement on U.S. Federal Trade Commission Challenge to Proposed Acquisition of Surmodics by Funds Affiliated with GTCR

FTC sues to block private equity firm's deal to buy medical device coatings maker Surmodics

Mar 6, 2025, 4:22 PM EST - 7 months ago

FTC sues to block private equity firm's deal to buy medical device coatings maker Surmodics

Top 3 Health Care Stocks You'll Regret Missing This Month

Feb 6, 2025, 7:01 AM EST - 8 months ago

Top 3 Health Care Stocks You'll Regret Missing This Month

DJT MRK

Surmodics Announces Successful Early Clinical Use of Pounce™ XL Thrombectomy System, Suitable for Non-Surgical Removal of Thrombi and Emboli from Iliac and Femoral Arteries

Feb 3, 2025, 7:00 AM EST - 8 months ago

Surmodics Announces Successful Early Clinical Use of Pounce™ XL Thrombectomy System, Suitable for Non-Surgical Removal of Thrombi and Emboli from Iliac and Femoral Arteries

Surmodics Reports First Quarter of Fiscal Year 2025 Financial Results

Jan 30, 2025, 7:00 AM EST - 8 months ago

Surmodics Reports First Quarter of Fiscal Year 2025 Financial Results

Surmodics Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Nov 6, 2024, 7:00 AM EST - 11 months ago

Surmodics Reports Fourth Quarter and Fiscal Year 2024 Financial Results

Surmodics Announces Early Results from PROWL Registry Study of Real-World Limb Ischemia Patients Treated with Pounce™ Thrombectomy System

Oct 30, 2024, 2:30 PM EDT - 1 year ago

Surmodics Announces Early Results from PROWL Registry Study of Real-World Limb Ischemia Patients Treated with Pounce™ Thrombectomy System

Surmodics Receives FDA 510(k) Clearance for Pounce™ XL Thrombectomy System, Expanding the Pounce Thrombectomy Platform to Larger Peripheral Arteries up to 10 mm in Diameter

Oct 1, 2024, 7:00 AM EDT - 1 year ago

Surmodics Receives FDA 510(k) Clearance for Pounce™ XL Thrombectomy System, Expanding the Pounce Thrombectomy Platform to Larger Peripheral Arteries up to 10 mm in Diameter

Surmodics Reports Third Quarter of Fiscal Year 2024 Financial Results

Jul 31, 2024, 7:00 AM EDT - 1 year ago

Surmodics Reports Third Quarter of Fiscal Year 2024 Financial Results

SURMODICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Surmodics, Inc. - SRDX

Jul 17, 2024, 4:31 PM EDT - 1 year ago

SURMODICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Surmodics, Inc. - SRDX

Surmodics Awarded Thrombectomy Products Agreement with Premier, Inc.

Jun 10, 2024, 7:00 AM EDT - 1 year ago

Surmodics Awarded Thrombectomy Products Agreement with Premier, Inc.

SURMODICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Surmodics, Inc. - SRDX

May 30, 2024, 10:30 PM EDT - 1 year ago

SURMODICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Surmodics, Inc. - SRDX

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Surmodics, Inc.

May 29, 2024, 6:36 PM EDT - 1 year ago

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Surmodics, Inc.

Surmodics Enters into Definitive Agreement to be Acquired by GTCR for $43.00 Per Share in Cash, Representing an Approximate Equity Value of $627 Million

May 29, 2024, 7:00 AM EDT - 1 year ago

Surmodics Enters into Definitive Agreement to be Acquired by GTCR for $43.00 Per Share in Cash, Representing an Approximate Equity Value of $627 Million

Surmodics, Inc. (SRDX) Q2 2024 Earnings Call Transcript

May 1, 2024, 4:07 PM EDT - 1 year ago

Surmodics, Inc. (SRDX) Q2 2024 Earnings Call Transcript

Surmodics Reports Second Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance

May 1, 2024, 7:00 AM EDT - 1 year ago

Surmodics Reports Second Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance

Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1

Apr 19, 2024, 7:00 AM EDT - 1 year ago

Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1

Surmodics to Participate in Upcoming Investor Conferences in March and April

Feb 27, 2024, 8:00 AM EST - 1 year ago

Surmodics to Participate in Upcoming Investor Conferences in March and April

Surmodics, Inc (SRDX) Q1 2024 Earnings Call Transcript

Feb 1, 2024, 2:41 PM EST - 1 year ago

Surmodics, Inc (SRDX) Q1 2024 Earnings Call Transcript

Surmodics Reports First Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance

Feb 1, 2024, 7:00 AM EST - 1 year ago

Surmodics Reports First Quarter of Fiscal Year 2024 Financial Results; Updates Fiscal Year 2024 Financial Guidance

Surmodics Announces Successful Early Clinical Use of Pounce™ LP (Low Profile) Thrombectomy System, Designed to Address a Critical, Unmet Need by Facilitating Removal of Thrombi and Emboli Below the Knee

Jan 22, 2024, 7:30 AM EST - 1 year ago

Surmodics Announces Successful Early Clinical Use of Pounce™ LP (Low Profile) Thrombectomy System, Designed to Address a Critical, Unmet Need by Facilitating Removal of Thrombi and Emboli Below the Knee

Surmodics to Host Virtual Annual Meeting of Shareholders

Jan 16, 2024, 7:30 AM EST - 1 year ago

Surmodics to Host Virtual Annual Meeting of Shareholders

Surmodics to Report First Quarter of Fiscal 2024 Financial Results on February 1

Jan 16, 2024, 7:30 AM EST - 1 year ago

Surmodics to Report First Quarter of Fiscal 2024 Financial Results on February 1

Surmodics Announces 24-Month Data from the SWING Trial Presented at VEITHsymposium

Nov 16, 2023, 7:30 AM EST - 2 years ago

Surmodics Announces 24-Month Data from the SWING Trial Presented at VEITHsymposium

Surmodics Announces TRANSCEND Trial 36-Month Data Presented at 50th Annual VEITH Symposium

Nov 16, 2023, 7:30 AM EST - 2 years ago

Surmodics Announces TRANSCEND Trial 36-Month Data Presented at 50th Annual VEITH Symposium

Surmodics to Participate in the Piper Sandler Healthcare Conference on November 28

Nov 14, 2023, 4:05 PM EST - 2 years ago

Surmodics to Participate in the Piper Sandler Healthcare Conference on November 28

Surmodics, Inc. (SRDX) Q4 2023 Earnings Call Transcript

Nov 10, 2023, 10:06 AM EST - 2 years ago

Surmodics, Inc. (SRDX) Q4 2023 Earnings Call Transcript

Surmodics Reports Fourth Quarter and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Financial Guidance

Nov 8, 2023, 7:30 AM EST - 2 years ago

Surmodics Reports Fourth Quarter and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Financial Guidance

Surmodics Announces SWING Trial 24-Month Data to be Presented at VEITH Symposium on November 15

Nov 7, 2023, 7:30 AM EST - 2 years ago

Surmodics Announces SWING Trial 24-Month Data to be Presented at VEITH Symposium on November 15

Surmodics Announces TRANSCEND Trial 36-Month Data to be Presented at 50th Annual VEITH Symposium

Nov 7, 2023, 7:30 AM EST - 2 years ago

Surmodics Announces TRANSCEND Trial 36-Month Data to be Presented at 50th Annual VEITH Symposium

Surmodics Announces Launch of Preside™ Medical Device Coating Technology, Providing Industry-Leading Lubricity and Durability to a Broader Range of Complex Device Applications

Oct 31, 2023, 7:30 AM EDT - 2 years ago

Surmodics Announces Launch of Preside™ Medical Device Coating Technology, Providing Industry-Leading Lubricity and Durability to a Broader Range of Complex Device Applications

Surmodics to Report Fourth Quarter and Fiscal 2023 Financial Results on November 8

Oct 10, 2023, 7:30 AM EDT - 2 years ago

Surmodics to Report Fourth Quarter and Fiscal 2023 Financial Results on November 8

Surmodics to Participate in Upcoming Investor Conferences in August

Aug 9, 2023, 5:05 PM EDT - 2 years ago

Surmodics to Participate in Upcoming Investor Conferences in August

Surmodics, Inc. (SRDX) Q3 2023 Earnings Call Transcript

Aug 6, 2023, 9:00 AM EDT - 2 years ago

Surmodics, Inc. (SRDX) Q3 2023 Earnings Call Transcript

Surmodics Reports Third Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance

Aug 2, 2023, 7:31 AM EDT - 2 years ago

Surmodics Reports Third Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance

Surmodics to Report Third Quarter of Fiscal 2023 Financial Results on August 2

Jul 12, 2023, 7:30 AM EDT - 2 years ago

Surmodics to Report Third Quarter of Fiscal 2023 Financial Results on August 2

Surmodics: Regulatory, Fundamental Catalysts Show 90% Upside Potential

Jun 22, 2023, 4:37 PM EDT - 2 years ago

Surmodics: Regulatory, Fundamental Catalysts Show 90% Upside Potential

Surmodics Receives FDA Approval for the SurVeil™ Drug-Coated Balloon

Jun 20, 2023, 6:30 AM EDT - 2 years ago

Surmodics Receives FDA Approval for the SurVeil™ Drug-Coated Balloon

Surmodics Receives FDA 510(k) Clearance for Pounce™ LP Thrombectomy System

Jun 14, 2023, 7:30 AM EDT - 2 years ago

Surmodics Receives FDA 510(k) Clearance for Pounce™ LP Thrombectomy System

Top 5 Health Care Stocks That Could Blast Off In May - Coherus BioSciences (NASDAQ:CHRS), Intercept Pharma (NASDAQ:ICPT)

May 26, 2023, 8:56 AM EDT - 2 years ago

Top 5 Health Care Stocks That Could Blast Off In May - Coherus BioSciences (NASDAQ:CHRS), Intercept Pharma (NASDAQ:ICPT)

CHRS ICPT

Surmodics to Participate in the Jefferies Healthcare Conference on June 8

May 25, 2023, 4:05 PM EDT - 2 years ago

Surmodics to Participate in the Jefferies Healthcare Conference on June 8

Surmodics, Inc (SRDX) Q2 2023 Earnings Call Transcript

Apr 26, 2023, 12:24 PM EDT - 2 years ago

Surmodics, Inc (SRDX) Q2 2023 Earnings Call Transcript

highnihilism
highnihilism Oct. 1 at 11:46 AM
$QCML Graniteshares 2X Long $QCOM Daily ETF Trades: 3 | Total $: 1.3 K | 0.48 × 90-Day Avg $: 2.6 K | Call $: 560 | Put $: 700 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $JQUA JPMorgan US Quality Factor ETF Trades: 6 | Total $: 9.4 K | 3.76 × 90-Day Avg $: 2.5 K | Call $: 560 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $SRDX Surmodics Trades: 6 | Total $: 761 | 0.01 × 90-Day Avg $: 66.1 K | Call $: 556 | Put $: 205 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $CQP Cheniere Energy Partners Trades: 11 | Total $: 9.5 K | 0.65 × 90-Day Avg $: 14.6 K | Call $: 555 | Put $: 8.9 K | Single-Leg: 100% | Multi-Leg: 0% | Contingent: –
0 · Reply
highnihilism
highnihilism Sep. 17 at 10:13 AM
IWM: Russell 2000 → $SRDX Surmodics $SVV Savers Value Village $THFF First Financial $PCYO Pure Cycle $SCVL Shoe Carnival
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 4 at 12:44 PM
$SRDX Great piece that accurately captures SRDX's current position. So if you want to refresh your understanding of SRDX or learn about SRDX for the first time, this is essential reading. https://beyondspx.com/quote/SRDX/surmodics-innovation-s-crucible-amidst-merger-uncertainty-nasdaq-srdx#analysis
0 · Reply
theoptionsplug
theoptionsplug Aug. 21 at 5:00 AM
Things to Watch Thursday (PART 2/2) 👁️ 🗣️7:30AM - Atlanta Fed President Raphael Bostic speaks 💼8:30AM - Initial jobless claims are released 📊9:45AM - Global flash PMIs for August arrive, with focus on U.S. tariffs after July’s manufacturing PMI slipped below 50. 🏘️10AM - Existing home sales data for July is released 👟 M&A Vote – Foot Locker $FL holds a shareholder meeting on its proposed merger with Dick’s Sporting Goods $DKS ⚖️ FTC Trial – Proceedings begin in the FTC’s attempt to block GTCR’s acquisition of Surmodics $SRDX
0 · Reply
ZacksResearch
ZacksResearch Aug. 12 at 6:34 PM
$SRDX surprises with a Q3 earnings beat, but challenges linger! 📊 SRDX delivered a surprise adjusted EPS of 6 cents, defying the Zacks Consensus Estimate of a 21-cent loss. However, fiscal Q3 revenues dipped 2.6% year over year, with declining Medical Device sales and a shrinking gross margin raising concerns. 📉 Complete risk/reward breakdown here 👉 https://www.zacks.com/stock/news/2703118/srdx-stock-up-following-q3-earnings-beat-gross-margin-contracts?cid=sm-stocktwits-2-2703118-body-7524&ADID=SYND_STOCKTWITS_TWEET_2_2703118_BODY_7524
0 · Reply
ZacksResearch
ZacksResearch Aug. 12 at 5:34 PM
$SRDX pops on Q3 beat 🔼 Earnings topped expectations with a narrower loss and revenue above estimates, even as SurVeil DCB sales slipped and gross margin contracted. Full earnings recap here 👉 https://www.zacks.com/stock/news/2703118/srdx-stock-up-following-q3-earnings-beat-gross-margin-contracts?cid=sm-stocktwits-2-2703118-teaser-7523&ADID=SYND_STOCKTWITS_TWEET_2_2703118_TEASER_7523
0 · Reply
traderhr
traderhr Aug. 12 at 9:47 AM
The stock chart for Surmodics shows a recent consolidation phase, with price movement stabilizing around the 38.00 level after a notable surge. The upper Bollinger Band indicates potential resistance at $SRDX #tradeideas $SPX $DJIA
0 · Reply
JarvisFlow
JarvisFlow Aug. 11 at 12:00 PM
Barrington Research has adjusted their stance on Surmodics ( $SRDX ), setting the rating to Market Perform.
0 · Reply
capribagholder
capribagholder Jun. 7 at 1:39 PM
$SRDX am i only one here hoping for 43 dollars 💸
0 · Reply
Estimize
Estimize Jun. 3 at 11:00 AM
Wall St is expecting -0.19 EPS for $SRDX Q3 [Reporting 07/30 BMO] http://www.estimize.com/intro/srdx?chart=historical&metric_name=eps&utm_c
0 · Reply
Estimize
Estimize May. 12 at 11:03 AM
Wall St is expecting -0.19 EPS for $SRDX Q3 [Reporting 07/30 BMO] http://www.estimize.com/intro/srdx?chart=historical&metric_name=eps&utm_c
0 · Reply
Estimize
Estimize Apr. 30 at 10:04 PM
$SRDX reported -0.13 EPS and 28.09 revenue for Q2. http://www.estimize.com/intro/srdx?chart=historical&metric_name=eps&utm_content=SRDX&utm
0 · Reply
d_risk
d_risk Apr. 30 at 1:41 PM
$SRDX - Surmodics Inc. Common Stock - 10Q - Updated Risk Factors SRDX faces new FTC litigation blocking its merger, adding regulatory hurdles and potential delays; merger closing now hinges on resolving FTC complaints and related costs. Global market uncertainties from tariffs and trade restrictions pose additional operational risks. #RegulatoryRisk #MarketUncertainty #TradeRestrictions #FTCLitigation #MergerChallenges 🟢 Added 🟠 Removed https://d-risk.ai/SRDX/10-Q/2025-04-30
0 · Reply
JarvisFlow
JarvisFlow Apr. 30 at 1:34 PM
Needham updates rating for Surmodics ( $SRDX ) to Hold.
0 · Reply
Estimize
Estimize Apr. 28 at 10:00 AM
Wall St is expecting -0.11 EPS for $SRDX Q2 [Reporting 04/30 BMO] http://www.estimize.com/intro/srdx?chart=historical&metric_name=eps&utm_c
0 · Reply
DonCorleone77
DonCorleone77 Apr. 22 at 11:50 AM
$SRDX Surmodics publishes TRANSCEND trial data Surmodics announced the publication of the TRANSCEND clinical trial, a global randomized study demonstrating the SurVeil drug-coated balloon is non-inferior to the IN.Pact Admiral DCB for safety and efficacy in patients with femoropopliteal arterial disease while using a substantially lower drug dose. The findings were published in the March edition of the European Journal of Vascular and Endovascular Surgery.
0 · Reply
Estimize
Estimize Apr. 17 at 10:06 AM
Wall St is expecting -0.11 EPS for $SRDX Q2 [Reporting 04/30 BMO] http://www.estimize.com/intro/srdx?chart=historical&metric_name=eps&utm_c
0 · Reply
Rust_Opera
Rust_Opera Apr. 15 at 6:38 PM
$SRDX Holly s... check this out... it’s starting to feel exactly like last time — retail circling, volume creeping, float still paper thin... someone’s moving early, I can feel it. I’ve seen this before. I’m already in. Wouldn’t be surprised if it rips — and fast. BUY BUY BUY... 🥳🤛🧨🚀
0 · Reply
JarvisFlow
JarvisFlow Mar. 7 at 9:10 PM
Lake Street updates rating for Surmodics ( $SRDX ) to Buy, target set at 43.
0 · Reply
PenkeTrading
PenkeTrading Feb. 1 at 12:22 PM
I found you an Oversold RSI (Relative Strength Index) on the daily chart of SurModics Inc. Is that bullish or bearish? $SRDX #SurModics #RsiOversold #NASDAQ
0 · Reply
DonCorleone77
DonCorleone77 Jan. 30 at 12:27 PM
$SRDX Surmodics reports Q1 EPS (4c), consensus (12c) Reports Q1 revenue $29.92M, consensus $33.37M. "We were pleased with the efforts of our team during first quarter of fiscal 2025, which enabled Surmodics to deliver strong growth in revenue from both our medical device performance coatings royalties and sales of our Pounce thrombectomy platforms," said Gary Maharaj, President and CEO of Surmodics, Inc. "This performance helped to offset the year-over-year decrease in SurVeil DCB revenue, which was expected given the initial stocking shipments made in the prior year period, as well as the impact of order timing in our In Vitro Diagnostics business."
0 · Reply
StockComps
StockComps Jan. 16 at 3:15 PM
$SRDX How we feeling about this buyout? What cased the 10 percent drop!?
0 · Reply